Abiopharma

🔍 Global GP LLC (Executive)

Company: GLOBAL PARTNERS LP (GLP)

Report Date: 2026-06-12

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common units representing limited partner interests at $46.5 per share (Direct)
  Date: 2026-06-12 | Code: P | equity_swap_involved: 0 | shares_owned_after: 131,584.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1
• Acquired 5,000 shares of Common units representing limited partner interests at $46.69 per share (Direct)
  Date: 2026-06-15 | Code: P | equity_swap_involved: 0 | shares_owned_after: 136,584.00 | transaction_form_type: 4 | Footnotes: F1, F3, F1

Footnotes:

• F1: Global GP LLC is purchasing common units for the purpose of satisfying obligations pursuant to awards previously granted to directors and officers under the Global Partners LP Long-Term Incentive Plan ("LTIP"). The reporting person disclaims any pecuniary interest in these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for the purpose of Section 16.
• F2: The price reported in Column 4 is a weighted average price. These common units were purchased in multiple transactions at prices ranging from $45.90 to $47.00, inclusive. The reporting person undertakes to provide to Global Partners LP, any security holder of Global Partners LP, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of common units purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These common units were purchased in multiple transactions at prices ranging from $46.25 to $47.14, inclusive. The reporting person undertakes to provide to Global Partners LP, any security holder of Global Partners LP, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of common units purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.